Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1994 Jan;93(1):303–310. doi: 10.1172/JCI116960

A unique property of a plasma proteoglycan, the C1q inhibitor. An anticoagulant state resulting from its binding to fibrinogen.

D K Galanakis 1, B Ghebrehiwet 1
PMCID: PMC293766  PMID: 8282801

Abstract

The C1q inhibitor, C1qI, an approximately 30-kD circulating chondroitin-4 sulfate proteoglycan, displayed concentration-dependent prolongation of plasma and fibrinogen solution clotting times. Under factor XIIIa catalyzed cross-linking conditions and maximum C1qI concentrations, minor amounts of clot formed displaying complete gamma-gamma dimer formation but virtually no alpha-polymer formation. The anticoagulant effect was undiminished by its binding to C1q, by increased ionic strength, and by CaCl2, but was abolished by incubation of C1qI with chondroitinase ABC. 125I-labeled C1qI bound to immobilized fibrinogen, fibrin monomer, fibrinogen plasmic fragments D1 and E, and fibrin polymers. Occupancy on the E domain required uncleaved fibrinopeptides together with another structure(s), and it did not decrease binding of thrombin to fibrinogen. Occupancy on the D domain did not decrease the fibrinogen binding to fibrin monomer. We conclude that the E domain occupancy impaired fibrinopeptide cleavage, and occupancy on the D domain impaired polymerization, both steric hindrance effects. C1qI binding to fibrinogen explains at least in part the well-known fibrin(ogen) presence in immune complex-related lesions, and the fibrinogen presence in vascular basement membranes and atheromata. We postulate that fibrin binding by resident basement membrane proteoglycans provides dense anchoring of thrombus, substantially enhancing its hemostatic function.

Full text

PDF
303

Images in this article

307Image
on p.307
307Image
on p.307

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bini A., Fenoglio J., Jr, Sobel J., Owen J., Fejgl M., Kaplan K. L. Immunochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions. Blood. 1987 Apr;69(4):1038–1045. [PubMed] [Google Scholar]
  2. Boinot C., Martin J., Larregue M. Heparin-like activity, atopic eczema, and contact dermatitis. Ann Intern Med. 1986 Aug;105(2):302–302. doi: 10.7326/0003-4819-105-2-302_1. [DOI] [PubMed] [Google Scholar]
  3. Bourin M. C., Lindahl U. Functional role of the polysaccharide component of rabbit thrombomodulin proteoglycan. Effects on inactivation of thrombin by antithrombin, cleavage of fibrinogen by thrombin and thrombin-catalysed activation of factor V. Biochem J. 1990 Sep 1;270(2):419–425. doi: 10.1042/bj2700419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carr M. E., Jr, Powers P. L. Effect of glycosaminoglycans on thrombin- and atroxin-induced fibrin assembly and structure. Thromb Haemost. 1989 Dec 29;62(4):1057–1061. [PubMed] [Google Scholar]
  5. Conradie J. D., Volanakis J. E., Stroud R. M. Evidence for a serum inhibitor of Clq. Immunochemistry. 1975 Dec;12(12):967–971. doi: 10.1016/0019-2791(75)90260-8. [DOI] [PubMed] [Google Scholar]
  6. Constantopoulos G., Rees S., Cragg B. G., Barranger J. A., Brady R. O. Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3700–3704. doi: 10.1073/pnas.77.6.3700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Doolittle R. F. Fibrinogen and fibrin. Annu Rev Biochem. 1984;53:195–229. doi: 10.1146/annurev.bi.53.070184.001211. [DOI] [PubMed] [Google Scholar]
  8. Entwistle R. A., Furcht L. T. C1q component of complement binds to fibrinogen and fibrin. Biochemistry. 1988 Jan 12;27(1):507–512. doi: 10.1021/bi00401a073. [DOI] [PubMed] [Google Scholar]
  9. Friman C., Nordström D., Eronen I. Plasma glycosaminoglycans in systemic lupus erythematosus. J Rheumatol. 1987 Dec;14(6):1132–1134. [PubMed] [Google Scholar]
  10. Galanakis D. K., Lane B. P., Simon S. R. Albumin modulates lateral assembly of fibrin polymers: evidence of enhanced fine fibril formation and of unique synergism with fibrinogen. Biochemistry. 1987 Apr 21;26(8):2389–2400. doi: 10.1021/bi00382a046. [DOI] [PubMed] [Google Scholar]
  11. Ghebrehiwet B. C1q inhibitor (C1qINH): functional properties and possible relationship to a lymphocyte membrane-associated C1q precipitin. J Immunol. 1981 May;126(5):1837–1842. [PubMed] [Google Scholar]
  12. Ghebrehiwet B., Silvestri L., McDevitt C. Identification of the Raji cell membrane-derived C1q inhibitor as a receptor for human C1q. Purification and immunochemical characterization. J Exp Med. 1984 Nov 1;160(5):1375–1389. doi: 10.1084/jem.160.5.1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Horne M. K., 3rd, Stein C. A., LaRocca R. V., Myers C. E. Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood. 1988 Feb;71(2):273–279. [PubMed] [Google Scholar]
  14. Iida J., Skubitz A. P., Furcht L. T., Wayner E. A., McCarthy J. B. Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin. J Cell Biol. 1992 Jul;118(2):431–444. doi: 10.1083/jcb.118.2.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jackson R. L., Busch S. J., Cardin A. D. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev. 1991 Apr;71(2):481–539. doi: 10.1152/physrev.1991.71.2.481. [DOI] [PubMed] [Google Scholar]
  16. Kaufman P. A., Gockerman J. P., Greenberg C. S. Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature. Am J Med. 1989 May;86(5):612–616. doi: 10.1016/0002-9343(89)90396-3. [DOI] [PubMed] [Google Scholar]
  17. Kehl M., Lottspeich F., Henschen A. Analysis of human fibrinopeptides by high-performance liquid chromatography. Hoppe Seylers Z Physiol Chem. 1981 Dec;362(12):1661–1664. [PubMed] [Google Scholar]
  18. Kolb W. P., Kolb L. M., Podack E. R. C1q: isolation from human serum in high yield by affinity chromatography and development of a highly sensitive hemolytic assay. J Immunol. 1979 May;122(5):2103–2111. [PubMed] [Google Scholar]
  19. LeBoeuf R. D., Gregg R. R., Weigel P. H., Fuller G. M. Effects of hyaluronic acid and other glycosaminoglycans on fibrin polymer formation. Biochemistry. 1987 Sep 22;26(19):6052–6057. doi: 10.1021/bi00393a016. [DOI] [PubMed] [Google Scholar]
  20. Liebman H. A., Comenzo R., Allen S. T., Dilorio J. M. A glycosaminoglycan inhibitor of thrombin: a new mechanism for abnormal hemostatic assays in cancer. Am J Hematol. 1991 Sep;38(1):24–29. doi: 10.1002/ajh.2830380105. [DOI] [PubMed] [Google Scholar]
  21. Lorand L., Urayama T., De Kiewiet J. W., Nossel H. L. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest. 1969 Jun;48(6):1054–1064. doi: 10.1172/JCI106061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Minguell J. J., Hardy C., Tavassoli M. Membrane-associated chondroitin sulfate proteoglycan and fibronectin mediate the binding of hemopoietic progenitor cells to stromal cells. Exp Cell Res. 1992 Jul;201(1):200–207. doi: 10.1016/0014-4827(92)90364-e. [DOI] [PubMed] [Google Scholar]
  23. Mosesson M. W., Sherry S. The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry. 1966 Sep;5(9):2829–2835. doi: 10.1021/bi00873a008. [DOI] [PubMed] [Google Scholar]
  24. Nossel H. L., Yudelman I., Canfield R. E., Butler V. P., Jr, Spanondis K., Wilner G. D., Qureshi G. D. Measurement of fibrinopeptide A in human blood. J Clin Invest. 1974 Jul;54(1):43–53. doi: 10.1172/JCI107749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rodgers G. M., Corash L. Acquired heparinlike anticoagulant in a patient with metastatic breast carcinoma. West J Med. 1985 Nov;143(5):672–675. [PMC free article] [PubMed] [Google Scholar]
  26. Ruoslahti E. Proteoglycans in cell regulation. J Biol Chem. 1989 Aug 15;264(23):13369–13372. [PubMed] [Google Scholar]
  27. Shainoff J. R., Page I. H. Deposition of modified fibrinogen within the aortic intima. Atherosclerosis. 1972 Nov-Dec;16(3):287–305. doi: 10.1016/0021-9150(72)90079-2. [DOI] [PubMed] [Google Scholar]
  28. Silvestri L., Baker J. R., Rodén L., Stroud R. M. The C1q inhibitor in serum is a chondroitin 4-sulfate proteoglycan. J Biol Chem. 1981 Jul 25;256(14):7383–7387. [PubMed] [Google Scholar]
  29. Smith E. B., Alexander K. M., Massie I. B. Insoluble "fibrin" in human aortic intima. Quantitative studies on the relationship between insoluble "fibrin", soluble fibrinogen and low density lipoprotein. Atherosclerosis. 1976 Jan-Feb;23(1):19–39. doi: 10.1016/0021-9150(76)90116-7. [DOI] [PubMed] [Google Scholar]
  30. Valenzuela R., Shainoff J. R., DiBello P. M., Urbanic D. A., Anderson J. M., Matsueda G. R., Kudryk B. J. Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas. Am J Pathol. 1992 Oct;141(4):861–880. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES